Despite these promising results, to confirm whether ADO pathway inhibition in combination with RFA therapy is key to most pancreatic cancer tumors, a similar approach studying RFA therapy with or without AB680 should also be performed in preclinical models with subcutaneous tumors from cell lines other than KPC as well as in orthotopic and GEM mice models. Here, ADO is linked to familial pancreatic carcinoma.